Silexion Therapeutics Initiates GMP Manufacturing for SIL204, Secures Phase 2/3 Trial Approval in Israel
SLXN sits 32% above its 52-week low of $0.47 on elevated volume (2.2× avg).
Summary
Silexion Therapeutics announced a significant advancement for its lead drug candidate, SIL204, by initiating Good Manufacturing Practice (GMP) clinical supply manufacturing with Catalent and securing approval from Tel Aviv Sourasky Medical Center for its planned Phase 2/3 trial in locally advanced pancreatic cancer. This dual progress marks a critical step towards first patient dosing and materially advances the company's clinical readiness. This positive operational and regulatory news comes shortly after the company's recent 8-K filing regarding a reverse stock split and increased authorized shares, which were necessary to fund operations given a prior going concern warning. The initiation of late-stage trial activities provides a crucial potential catalyst for the micro-cap company, offering a path to value creation amidst its financial challenges. Investors will now watch for updates on patient enrollment and trial initiation.
At the time of this announcement, SLXN was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.47 to $22.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.